FibroBiologics Reports Breakthrough in Bone Marrow Organoid Platform for Cancer and Immune System Regeneration
Key Insights
FibroBiologics (search) announced significant advancements in its proprietary Bone Marrow Organoid platform, demonstrating potential for treating hematopoietic cancers (search) and age-related immune decline (search).
Pre-IND animal trials showed that transplantation of Bone Marrow Organoids (search) into xenografted melanoma (search) mouse models significantly reduced tumor size.
The platform enables efficient ex vivo gene editing and cryopreservation capabilities, offering scalable treatment options for bone marrow transplantation.
FibroBiologics (search), Inc. (Nasdaq: FBLG) announced significant advancements in its proprietary Bone Marrow Organoid platform on September 10, 2025, revealing promising new treatment options for hematopoietic cancers (search) and age-related immune decline (search). The clinical-stage biotechnology company, which holds over 270 patents issued and pending, demonstrated multiple therapeutic applications for its innovative organoid technology.
Preclinical Efficacy in Cancer Treatment
The company's Pre-IND animal trials showed that transplantation of Bone Marrow Organoids (search) into xenografted melanoma (search) mouse models significantly reduced tumor size. This breakthrough represents a crucial milestone in the platform's development toward clinical applications for cancer treatment.
The organoids demonstrate three key capabilities that distinguish them from traditional approaches: efficient ex vivo gene editing allowing for swift and targeted therapeutic interventions before transplantation, cryopreservation capabilities offering scalable and readily available treatment options for bone marrow transplantation, and versatility across multiple therapeutic applications.
Expanding Beyond Cancer Treatment
"Our organoid platform has the potential to do much more than target cancer," said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics (search). "We see potential opportunities to help regenerate one or more desired immune cell type, counter age-related immune system decline, and restore immune function in patients with a compromised immune system. Looking ahead, this approach could also potentially enable the in-vivo generation of advanced cell therapies, such as CAR-T and CAR-NK cells (search), directly within patients."
The platform's potential extends to addressing age-related immune system decline and restoring immune function in patients with compromised immune systems. This broad therapeutic scope positions the technology as a versatile solution for multiple clinical challenges in oncology and immunology.
Clinical Development Pathway
Pete O'Heeron, Founder and Chief Executive Officer of FibroBiologics (search), emphasized the significance of these developments: "These breakthroughs are an important milestone in the journey to transform the way we approach cancer and immune-related diseases. Our pilot studies are laying the foundation for IND-enabling preclinical development and positioning our Bone Marrow Organoid technology for clinical advancement. The real power of this platform is its versatility and scalability, designed to deliver meaningful impact across multiple therapeutic areas."
The company is positioning its pilot studies as the foundation for IND-enabling preclinical development, indicating progression toward regulatory submissions and eventual clinical trials.
Technology Platform Advantages
FibroBiologics (search)' approach leverages fibroblast cells and fibroblast-derived materials to develop treatments for chronic diseases. The Bone Marrow Organoid platform represents a significant expansion of the company's therapeutic pipeline, which already includes applications in wound healing, multiple sclerosis (search), disc degeneration, psoriasis (search), orthopedics, human longevity, and cancer.
The cryopreservation capability of the organoids addresses a critical challenge in cell therapy manufacturing and distribution, potentially enabling off-the-shelf availability for bone marrow transplantation procedures. This scalability factor could significantly impact treatment accessibility and cost-effectiveness in clinical practice.